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Background: Profound synapse loss is one of the major pathological hallmarks associated with Alzheimer’s disease,
which might underlie memory impairment. Our previous work demonstrates that magnesium ion is a critical factor
in controlling synapse density/plasticity. Here, we tested whether elevation of brain magnesium, using a recently
developed compound (magnesium-L-threonate, MgT), can ameliorate the AD-like pathologies and cognitive deficits
in the APPswe/PS1dE9 mice, a transgenic mouse model of Alzheimer’s disease.
Results: MgT treatment reduced Aβ-plaque, prevented synapse loss and memory decline in the transgenic mice.
Strikingly, MgT treatment was effective even when the treatment was given to the mice at the end-stage of their
Alzheimer’s disease-like pathological progression. To explore how elevation of brain magnesium ameliorates the
AD-like pathologies in the brain of transgenic mice, we studied molecules critical for APP metabolism and signaling
pathways implicated in synaptic plasticity/density. In the transgenic mice, the NMDAR signaling pathway was
downregulated, while the BACE1 expression were upregulated. MgT treatment prevented the impairment of
these signaling pathways, stabilized BACE1 expression and reduced sAPPβ and β-CTF in the transgenic mice. At
the molecular level, elevation of extracellular magnesium prevented the high Aβ-induced reductions in synaptic
NMDARs by preventing calcineurin overactivation in hippocampal slices.
Conclusions: Our results suggest that elevation of brain magnesium exerts substantial synaptoprotective effects in a
mouse model of Alzheimer’s disease, and hence it might have therapeutic potential for treating Alzheimer’s disease.
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Dysfunctions in the metabolic processes of amyloid pre-
cursor protein (APP) are widely hypothesized to underlie
Alzheimer’s disease (AD) [1,2]. In this scenario, increases
in concentration of several potentially toxic peptides in-
cluding sAPPβ and β-CTF [3], N-APP [4] or small Aβ
oligomers lead to the formation of Aβ-plaques, synapse
dysfunction/loss, neuronal loss and overall brain atro-
phy, which cause decline of cognitive abilities [2,5].
Therefore, designing therapeutic agents that target APP
metabolic processes is among the major strategies being
pursued in the quest to treat AD [1]. However, these* Correspondence: liu.guosong@gmail.com
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unless otherwise stated.agents have not been shown to slow/reverse the cogni-
tive deficits in AD patients [1].
Although dysfunctions in APP metabolism are a strong
predictor for developing AD, Aβ-plaque density does not
always correlate with the decline in cognitive abilities [6].
For example, some Aβ-plaque-positive individuals have no
signs of brain atrophy [7], and highly educated subjects
seem to tolerate high levels of Aβ-plaques without cogni-
tive impairment [8]. Thus, while dysfunctions in APP me-
tabolism might be necessary, it does not appear sufficient
for developing AD-associated atrophy and cognitive im-
pairment [9].
Numerous studies demonstrate that elevation of soluble
Aβ in the brain could impair synaptic function and reduce
synapse density [2,10]. However, synaptic plasticity andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[11], with some having neuro-/synapto-trophic functions.
Hence, a balance between APP-derived neurotoxic pep-
tides and neuro-/synapto-trophic factors might ultimately
determine the rate of decline in synaptic and cognitive
functions in AD. Indeed, several endogenous neurotrophic
factors are effective in counteracting the synapse and
memory loss in animal models of AD. For example, ad-
ministration of the peptide cerebrolysin [12], the octapep-
tide NAP [13], nerve growth factor (NGF) [14], or brain
infusion of brain-derived neurotrophic factor (BDNF)
[15], in rodent and primate AD models reverses synapse
loss or rescues learning and memory. In humans, intrana-
sal administration of insulin improves cognition in early
AD [16]. Therefore, protecting existing synapses and/or
promoting synapse generation/regeneration by increasing
trophic factors in brain might present an alternative strat-
egy to ameliorate memory deficits in AD.
Our previous studies indicate that the magnesium ion
(Mg2+) is a critical factor in controlling synapse density/
plasticity [17]. We have shown that elevation of brain mag-
nesium by a novel compound (Mg-L-threonate, MgT)
upregulates NMDAR signaling, prevents synapse loss and
reverses memory deficits in aged rats [18]. If impairment
in cognitive functions in AD patients is mainly caused by
synapse failure/loss [19], it becomes tempting to test
whether elevation of brain magnesium could still be effect-
ive under AD-like pathological conditions. Furthermore,
brain magnesium level [20] and serum Mg2+ concentration
[21] appear to be significantly lower in AD patients com-
pared with age-matched normal subjects. If so, then simply
restoring brain magnesium might beneficiate AD patients.
Here, we show that elevation of brain magnesium pre-
vents/reverses synapse loss and memory deficits in a trans-
genic mouse model of AD and reveal the possible
underlying mechanism.Results
Elevation of brain magnesium prevented learning and
memory deficits in APPswe/PS1dE9 transgenic mice
We chose the APPswe/PS1dE9 transgenic mouse as an
animal model of AD (referred to as Tg mice) that ex-
hibits high brain amyloid deposits [22] and severe defi-
cits in spatial memory at 6–7 months of age [23-25]. In
our previous study in rats, the effective dosage for mem-
ory enhancement by MgT was 50 mg/kg/day elemental
Mg [18]. The equivalent elemental magnesium dose in
mice is 75 mg/kg/day (910 mg/kg/day MgT) [26]. This
dose was effective in elevating Mg2+ concentration in
plasma and red blood cells (Figure 1G and H). Interest-
ingly, we found that Mg2+ concentration in the plasma
of untreated Tg mice was significantly lower than that of
WT mice (Figure 1G), those data are inline with previousstudies showing reductions in Mg2+ concentration in the
serum of AD patients [21].
We tested whether elevating brain magnesium could
prevent learning and memory deficits in Tg mice. MgT
treatment started at 6 months of age. After 1 month of
MgT treatment, we assessed spatial learning and mem-
ory abilities using the water maze task. Untreated Tg
mice exhibited unequivocal learning deficits in this task
at 7 months of age. MgT-treated Tg mice (Tg +MgT), in
contrast, performed quite similar to WT (Figure 1A).
When we did a probe test 24 h after the last training
trial, untreated Tg mice showed no preference toward
the target quadrant, indicating significant memory im-
pairment, while Tg +MgT mice performed as well as
WT (Figure 1B).
The improvement of cognitive functions after 1 month
treatment with MgT is interesting. However, from thera-
peutic point of view, efficacy of MgT on cognitive function
over a longer time-course is more important. To check if
MgT remained effective over a long-term treatment, the
same groups of mice were retested at 15 and 22 months
of age (after 9 and 16 months of MgT treatment, respect-
ively). At 15 months, learning and memory abilities were
reassessed using the same water maze task (modified
protocol, see Methods). Tg mice completely lost their abil-
ity to locate the hidden platform, while Tg +MgT and WT
mice could readily locate it (Figure 1C). In the probe test,
Tg +MgT mice, similar to WT, spent significantly more
time in the target quadrant compared with other quad-
rants, while untreated Tg mice swam randomly (Figure 1D).
We did not observe significant differences in the velocity,
in the water maze, among the three groups of mice at both
ages of 7 and 15 months (Table 1), indicating that the dif-
ferences in latencies/time-in-quadrant among the groups
were not because the untreated Tg mice swam slower than
other mice.
At 22 months, we assessed short- and long-term recog-
nition memory (STM and LTM) using a modified version
of the standard novel-object recognition task (NORT).
The NORT was selected to avoid repeating the water
maze task for the third time and because the mice were
too weak to perform the water maze task at age of
22 months. During the STM test (10 m retention interval),
Tg mice did not show any preference toward the novel ob-
ject. In contrast, WT and Tg +MgT mice spent signifi-
cantly more time exploring the novel object (Figure 1E,
left). During the LTM test (24 h retention interval) only
WT and Tg +MgT mice exhibited clear preference toward
the novel object (Figure 1E, right). Thus, MgT treatment
remained effective after long-term (up to 16 months)
treatment.
To confirm that MgT treatment was associated with
elevating brain magnesium, we quantified the magne-
sium contents (total magnesium in tissue) in brain and
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Figure 1 (See legend on next page.)
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Figure 1 Prevention of memory deficits in APPswe/PS1dE9 transgenic mice (Tg mice) by MgT treatment. (A) Escape latencies in seconds(s)
during training (5 trials/day) in water maze task at 7 months of age, i.e., after 1 month of treatment. Three groups of mice were used; WT
(n = 9), Tg (n = 13) and Tg +MgT (n = 9; ANOVA effect of treatment, p < 0.05). (B) Probe test conducted 24 h after the training. Top, representative
path tracings. Bottom, percentage of time spent in each quadrant (ANOVA differences among quadrants; WT: p < 0.05; Tg +MgT: p < 0.0001).
(C) Same as (A) and on the same mice, but tested at 15 months of age. WT (n = 9); Tg (n = 7); Tg + MgT (n = 6). ANOVA effect of treatment p < 0.05.
(D) Probe test 24 h later (ANOVA differences among quadrants: WT: p < 0.0001; Tg + MgT: p < 0.0001). (E) Short-term (10 m in retention interval, left)
and long-term (24 h, right) novel-object recognition memory tests performed on the same group of mice at 22 months of age. WT (n = 7), Tg
(n = 6), and Tg +MgT (n = 6). Recognition index calculated as percentage of time spent exploring each object (Obj1-3). Black bars indicate novel
object (Nov). ANOVA differences in recognition index of different objects in WT (STM: p < 0.0001; LTM: p < 0.0001) and Tg +MgT (STM: p < 0.0001;
LTM: p < 0.001). Dashed lines represent chance levels of performance (25%). (F) Total magnesium (ionized and non-ionized) contents in different
organs/tissues (Mgtissue) normalized to tissue weight (mg/g) in the same groups of mice. WT (n= 7), Tg (n= 6) and Tg +MgT (n= 6). ANOVA difference
among groups (brain: p < 0.0001; kidney: p < 0.01). (G) Magnesium ion concentration in the plasma ([Mg2+]plasma, mM) of WT (n = 14), Tg (n = 9) and
Tg +MgT mice (n = 8) as measured by the calmagite method. ANOVA difference among groups (p< 0.01). (H) The intracellular free Mg2+ concentration
in the red blood cell ([Mg2+]RBC) of WT (n = 12), Tg (n = 11) and Tg +MgT mice (n = 11) as measured by the flow cytometry method (fluorescent optical
density, OD). ANOVA difference among groups (p < 0.05). ANOVA was followed by Bonfferoni’s post hoc test. (I) Brain total magnesium content (Mgbrain,
mg/g), in Tg mice (23 months old), significantly correlated with the recognition index in the short-term recognition memory test (Pearson’s test). Data
from Tg +MgT mice (23 months old treated for 17 months) are displayed, but were not included in the correlation analysis. Error bars show SEM.
* p< 0.05, *** p< 0.001.
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tioned above (perfused at age of 23 month). MgT treat-
ment selectively elevated Mg2+ content in brain and
kidneys (Figure 1F) of Tg mice. Interestingly, in un-
treated Tg mice, brain magnesium level positively corre-
lated with their cognitive function; the lower their brain
magnesium, the poorer their memory function in the
NORT task (Pearson’s test, r2 = 0.77, p = 0.02, Figure 1I).
We did not observe significant side effects over the en-
tire time-course of MgT treatment (Table 1).
Elevation of brain magnesium prevented synapse loss in
APPswe/PS1dE9 transgenic mice
To study the cellular mechanisms underlying the pre-
vention of memory deficits in Tg mice by MgT, we ex-
amined effects of this treatment on synapse density. The
brains of the same mice used in the above-described be-
havioral experiments (Figure 1) were subjected to histo-
logical analysis. First, we quantified synapse density in
the hippocampus, a brain region critical for memory
function. Tg mice had a significantly lower number of
synapses (by ~25.3%) compared to WT; this synapse loss
was prevented by MgT treatment (Figure 2A, for
ANOVA analysis see Table 2). We also checked the total
presynaptic terminal density, using the synaptic vesicleTable 1 Body weight, food/fluid intake, and locomotor activit
Tg +MgT (n = 6) mice and the velocity in the water maze task











WT 42.84 ± 3.92 4.08 ± 0.61 7.16 ± 0.26 5.72 ± 0.75
Tg 40.87 ± 10.80 3.41 ± 1.48 6.83 ± 0.71 4.34 ± 0.48
Tg +MgT 39.73 ± 3.57 3.69 ± 0.74 6.25 ± 1.00 5.03 ± 0.32
On way ANOVA revealed no significant differences among the three groups of micemarker synaptophysin, in the hippocampal dentate gyrus
(DG). In Tg mice there were significantly fewer synaptic
puncta (~32.5%) than those in WT mice. MgT treatment
prevented this reduction in Tg mice (Figure 2B and
Table 2).
Next, we examined the effects of MgT treatment on
GABAergic terminals by quantifying density of glutamic
acid decarboxylase 65 kD (GAD65) labeled puncta. Tg
mice had significantly lower immunostained puncta
density for GAD65 (~33.3%, Figure 2C and Table 2) than
WT. MgT treatment prevented the loss in GABAergic
terminals (Figure 2C).
To determine the functional consequences of synapse
density reduction on glutamatergic synaptic transmis-
sion, we compared the input–output relationship of hip-
pocampal CA1 synapses in vivo, in a separate group of
mice (15 months old, MgT treatment for 9 months).
The amplitude of field postsynaptic potentials (fPSPs)
for a given stimulus intensity was significantly lower in
Tg mice compared to WT, while Tg +MgT mice had a
similar input–output relationship as WT (Figure 2D).
Therefore, MgT treatment was also effective in prevent-
ing reductions in glutamatergic synaptic transmission.
Finally, we plotted the relationship between synapse
density and short-term memory (quantified by they in the open field of wild-type (WT, n = 7), Tg (n = 6) and
of WT, Tg and Tg +MgT mice at age of 7 months (n = 9,
ctivity in the open field Velocity in the water maze (cm/s)
/s) Distance travelled (cm) 7 months old 15 months old
3403.99 ± 443.13 11.2 ± 1.1 12.9 ± 2.6
2573.52 ± 286.99 9.9 ± 1.1 11.1 ± 1.9
2954.00 ± 159.68 10.8 ± 1.5 11.8 ± 2.4
. Data presented as mean ± SD.










































































































Figure 2 Prevention by MgT treatment of synapse loss in APPswe/PS1dE9 transgenic mice (Tg mice). (A) Left: electron microscopic
images showing structural synapses (blue arrows) in hippocampal outer molecular layer of dentate gyrus (DG-OML). Right: Estimated synaptic
density. WT (n = 6), Tg (n = 6) and Tg +MgT (n = 5). (B) Left: Immunostaining of synaptophysin-positive terminals (Syn Puncta) in DG-OML. Right:
Quantitative analysis of Syn Puncta (n = 6/group). (C) Same as in (B) and from same groups of mice; however, puncta represent GABAergic
(GAD65). (D) Input–output (normalized) relationship of hippocampal CA1 synapses in vivo (n = 6/group). Field post synaptic potentials (fPSPs)
were normalized by the maximum amplitude of fPSPs. Two Way ANOVA revealed significant effects of treatment: p < 0.05; and stimulus:
p < 0.0001. (E) Correlation between the density of Syn Puncta and short-term recognition memory in Tg mice (23 months old). Tg +MgT
(23 months old treated for 17 months) data are displayed but were not included in the regression analysis (Pearson’s test). Error bars show SEM.
* p < 0.05, ** p < 0.01, *** p < 0.001.
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performance correlated with the density of synaptophysin
puncta (r2 = 0.78, p = 0.02, Figure 2E), suggesting that syn-
apse loss might be one of primary factors underlying mem-
ory deficits in Tg mice.
Impairment of NMDAR signaling in APPswe/PS1dE9
transgenic mice
During learning and memory processes, correlated syn-
aptic inputs activate NMDARs, leading to activation ofdownstream signaling molecules and increase in ex-
pression of genes necessary for synaptic remodeling
[27]. Having demonstrated that Tg mice have signifi-
cant reductions in structural synapse density and gluta-
matergic synaptic transmission, we next evaluated
whether activation of NMDAR signaling still occurs in
the remaining synapses following environmental en-
richment behavioral stimulation. The environmental
enrichment-based stimulus was chosen because it will
evoke physiologic neuronal inputs.
Table 2 One-way ANOVA analysis of the electron microscopy, immunostaining and Western blot data
Value Basal Stimulation
F value P value Figure F value P value FigureProtein
Structural synapses F(2,14) = 7.243 0.0069 Figure 2A NA NA NA
Synaptophysin F(2,15) = 26.21 <0.0001 Figure 2B NA NA NA
GAD65 F(2,15) = 4.130 0.0373 Figure 2D NA NA NA
NR2B/GAPDH F(2,12) = 1.026 0.3877 Figure 3B F(2,14) = 55.26 <0.0001 Figure 3B
pCamkII/CamkII F(2,12) = 0 1 Figure 3C F(2,14) = 4.269 0.0357 Figure 3C
pCreb/Creb F(2,12) = 0 1 Figure 3D F(2,14) = 9.883 0.0021 Figure 3D
BACE1/GAPDH F(2,12) = 28.70 < 0.0001 Figure 5C F(2,14) = 60.76 <0.0001 Figure 5C
Synaptophysin NA NA NA F(2,16) = 20.15 <0.0001 Figure 7F
NA: not applicable.
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18 month, MgT treatment was given for 12 months) and
compared the expression/phosphorylation of NMDAR
signaling key proteins using quantitative Western blot-
ting. Mice from each group were divided into two
halves, one half was sacrificed under home-cage condi-
tions (basal) and the second half was sacrificed following
24 h of environmental enrichment-based stimulation.
Under basal conditions, the NMDAR signaling appeared
to be identical between WT and Tg mice. Interestingly,
environmental stimulation induced increases in NR2B
expression (by 167%, Figure 3A and B), CaMKII activa-
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Figure 3 Prevention by MgT treatment of impairment in NMDAR sign
(A) Representative Western blots showing the expression levels of NR2B, p
sacrificed either after home-cage conditions (basal) or following 24 h of en
expression served as loading control. (B) Left: Quantitative analysis of NR2B
(n = 5/group), obtained by Western blot (arbitrarily units, a.u.). Mice were sa
Quantitative analysis of NR2B expression the hippocampus of WT (n = 6), Tg
behavioral stimulation. (C and D) same as (B) but quantifying Phosphorylat
(pCREB)/CREB ratio (D). ANOVAs (Table 2) were followed by Bonferroni’s poactivation (pCREB, by 399%, Figure 3A and D) in WT
but not in Tg mice. MgT treatment rescued these defi-
cits (Figure 3 and Table 2). Thus, dysfunction of APP
metabolism not only triggered synapse loss and reduction
of synaptic transmission, but also impaired activation of
NMDAR signaling by correlated synaptic inputs, which
might result in loss of the plasticity in the remaining
synapses. The expression/activation pattern of NMDAR
signaling in Tg +MgT mice was almost identical to
WT, in both basal and stimulated conditions. There-
fore, MgT treatment might protect NMDAR signaling





































































Basal Stim Basal  Stim
Basal Stim
aling pathway in APPswe/PS1dE9 transgenic mice (Tg mice).
CaMKII, CaMKII, pCREB, and CREB in the hippocampus of mice
vironmental enrichment-based behavioral stimulation (Stim). GAPDH
expression in the hippocampus of WT, Tg and Tg + MgT mice
crificed under basal conditions without behavioral stimulation. Right:
(n = 6) and Tg + MgT mice (n = 5) obtained by Western blot following
ed CaMKII (pCaMKII)/CaMKII ratio (C) and Phosphorylated CREB
st hoc test. Error bars show SEM. * p < 0.05, *** p < 0.001.
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of NMDAR synaptic transmission by elevation of [Mg2+]o
It is clear that MgT treatment not only prevented syn-
apse loss in Tg mice, but also restored the functionality
of NMDAR signaling in the remaining synapses. Since
NMDARs are essential for synaptic plasticity and mem-
ory functions, we conducted the following experiments
to explore, mechanistically, how elevation of Mg2+ can
protect NMDARs from Aβ-induced downregulation.
First, we studied the molecular mechanisms under-



















Figure 4 Prevention of exogenous Aβ42-induced downregulation of s
Representative traces of EPSCs recorded at membrane potentials of −70 an
(red) application of Aβ42 with (right) or without (left) the addition of calcin
[Mg2+]o (1.2-[Mg
2+]o). Lower panel: EPSCs at 0.8 and 1.2 mM [Mg
2+]o with a
(ifenprodil). (B) The ratio of amplitudes of EPSCNMDAR to EPSCAMPA (INMDA/A
Aβ42 + FK506 (n = 8) slices. ANOVA revealed significant difference among t
hoc test. ** p < 0.01, ***p < 0.001. (C) The ratio of amplitudes of EPSCNMDAR
n = 6), 0.8-[Mg2+]o + FK506 (n = 7) and 1.2-[Mg
2+]o + FK506 slices (n = 7). (D)
0.8-[Mg2+]o (n = 8), 1.2-[Mg
2+]o + Aβ42 (n = 6), 0.8-[Mg
2+]o + FK506 (n = 7) an
and 1.2-[Mg2+]o + Aβ42 + FK506 (n = 8). (E) The ratio of amplitudes of EPSC
0.8-[Mg2+]o (n = 6), 0.8-[Mg
2+]o + Aβ42 (n = 10), 1.2-[Mg2+]o (n = 8) and 1.2-[
acute hippocampal slices from 4 weeks old WT mice. Unpaired t-tests, ** p
impairs NMDARs and how elevation of [Mg2+]o might prevent this impairmEPSCAMPA between CA3-CA1 synaptic connections
(Shaffer collaterals) was recorded in hippocampal slices
using whole-cell patch-clamp recordings from CA1 pyr-
amidal neurons while stimulating Shaffer collaterals at
low frequency (0.03 Hz). Exogenous application of Aβ
(1 μM for 1 h at room temperature) significantly re-
duced INMDA (by ~48%), when brain slices were bathed
under physiological extracellular magnesium concentra-
tion ([Mg2+]o = 0.8 mM, referred to as 0.8-[Mg
2+]o slices,
Figure 4B). A previous study suggests that downregula-







































































































ynaptic NMDARs by elevation of [Mg2+]o. (A) Top panel:
d +50 mV at 0.8 mM [Mg2+]o (0.8-[Mg
2+]o) before (black) and after
eurin inhibitor (FK506). Middle panel: Same as above but at 1.2 mM
nd without Aβ42 monomers in the presence of NR2B blocker
MPA) in 0.8-[Mg
2+]o (n = 8), 0.8-[Mg
2+]o + Aβ42 (n = 7) and 0.8-[Mg2+]o +
he groups (p < 0.0001). ANOVA was followed by Bonferroni’s post
to EPSCAMPA (INMDA/AMPA) in 0.8-[Mg
2+]o (n = 8), 1.2-[Mg
2+]o (green,
The ratio of amplitudes of EPSCNMDAR to EPSCAMPA (INMDA/AMPA) in
d 1.2-[Mg2+]o + FK506 slices (n = 7), 0.8-[Mg
2+]o + Aβ42 + FK506 (n = 8)
NMDAR to EPSCAMPA (INMDA/AMPA) after the addition of ifenprodil;
Mg2+]o + Aβ42 (n = 12). Recordings were conducted, in vitro, using
< 0.01. Error bars show SEM. (F) Schematic illustration of how high Aβ
ent.
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observations and found that inhibition of calcineurin
(FK506, 10 μM for 1 h) was effective in preventing
downregulation of NMDARs by Aβ in hippocampal
slices (Figure 4B). Therefore, calcineurin might be the
molecular target mediating the Aβ-induced downregula-
tion of NMDARs.
Next, we tested whether calcineurin is also involved in
the molecular mechanism underlying the upregulation of
NMDARs by elevation of [Mg2+]o [17,18]. As expected,
elevation of [Mg2+]o (to 1.2 mM, 1.2-[Mg
2+]o slices), in-
creased INMDA (by ~53%, percentage of 0.8-[Mg
2+]o slices,
Figure 4C). Interestingly, in the presence of the calcine-
urin inhibitor, INMDA increased in 0.8-[Mg
2+]o (Figure 4C),
while INMDA in 1.2-[Mg
2+]o remained the same such
that the amplitudes of INMDA under 0.8-[Mg
2+]o and
1.2-[Mg2+]o slices were almost identical (Figure 4C).
Those data imply that elevation of [Mg2+]o might up-
regulate INMDA by inhibiting calcineurin signaling. If
both Aβ and [Mg2+]o influence INMDA by controlling
the activity of calcineurin, then elevation of brain mag-
nesium might be able to prevent overactivation of cal-
cineurin by high Aβ, resulting in protection of
NMDARs. Indeed, in the presence of higher [Mg2+]o
(1.2 mM), the amplitude of INMDA current under ex-
ogenous Aβ was almost identical to that in 0.8-[Mg2+]o
control slices (incubated under Aβ free and physio-
logical [Mg2+]o conditions, Figure 4D). To prove that
this protection is mediated by calcineurin, we compared
the size of INMDA under high Aβ, high/low [Mg
2+]o,
or both in the presence of calcineurin inhibitor. INMDA
was identical in all slices regardless of the presence of
high Aβ or [Mg2+]o (Figure 4D). Thus, elevation of brain
magnesium might protect NMDARs in the Tg mice by
preventing over-activation/-expression of calcineurin
(Figure 4F).
Finally, we studied the effects of Aβ on INMDA after
blocking NR2B-containing NMDARs with ifenprodil
(3 μM for 10 m before recording). NR2A-containing
NMDARs in 0.8- and 1.2-[Mg2+]o slices were unaffected
by Aβ (Figure 4E), suggesting that the reduction of INMDA
after Aβ application was largely due to reduction of synap-
tic NR2B-portion of NMDARs, whereas elevated -[Mg2+]o
prevented this downregulation.
Effects of elevating brain magnesium on amyloid plaques
and BACE1 expression
Having demonstrated that elevating brain magnesium can
protect NMDAR signaling, we explored whether elevation
of brain magnesium can affect APP metabolism, which
might also contribute to the retained cognitive abilities in
MgT-treated Tg mice. We, first, quantified amyloid plaques
density, using the anti-Aβ-antibody 6E10, in the hippocam-
pus and frontal cortex. At 23 months of age, ~12% of thehippocampal area in Tg mice was occupied by amyloid pla-
ques. MgT treatment (for 17 months) reduced the amyloid
plaque area significantly (by ~35.8%, Figure 5A, upper
panel). A similar percentage of reduction was observed in
the frontal cortex (by ~36%, Figure 5A, lower panel). These
observations were confirmed by another anti-Aβ-antibody
(4G8, data not shown). We checked the concentrations of
Aβ42 and Aβ40 monomers in the cerebrospinal fluid
(CSF) of a separate group of Tg mice (14 months old, MgT
treatment for 8 months). The concentration of Aβ42 was
elevated in the CSF of Tg mice. Surprisingly, despite the
significant reduction in the amyloid plaques density, CSF
concentration of both Aβ monomers was unaltered by
MgT treatment (Figure 5B).
To study the molecular mechanisms underlying the re-
duction of amyloid plaques by MgT treatment, we inves-
tigated the expression of β-secretase (BACE1) in the
three groups of mice using quantitative Western blot
analysis (brain homogenates from same mice in Figure 3,
see the Additional file 1: Figure S1 and Additional file 2:
Figure S2 for the raw data). Under home-cage and fol-
lowing environmental enrichment-based stimulation, Tg
mice had significantly higher BACE1 expression levels
than WT mice (Figure 5C). Interestingly, MgT treatment
prevented overexpression of BACE1 under both basal
and stimulated conditions in Tg mice (Figure 5C and
Table 2). To check if the reductions in BACE1 by MgT
lead to reductions in the synaptotoxic products of
BACE1; namely sAPPβ and β-CTF [3], we investigated
the expression of human sAPPβ and β-CTF in Tg and
Tg +MgT mice. We found that Tg +MgT mice had sig-
nificantly lower sAPPβ expression levels than untreated
Tg mice following environmental enrichment-based
stimulation (Figure 5D). Quantitative Western blot ana-
lysis also showed that Tg +MgT mice had significantly
lower β-CTF levels than untreated Tg mice under basal
conditions (Figure 5E). Thus, MgT treatment might re-
duce the production of APP synaptotoxic metabolites by
stabilizing the expression of BACE1 in Tg mice. These
results uncover a new and intriguing potential molecular
target of elevated brain magnesium in APP metabolism.
We have previously shown that MgT treatment upre-
gulates NR2B-containing NMDARs signaling and in-
creases synapse density in the hippocampus of wild type
young and aged rats [18]. The intriguing stabilization of
BACE1 expression by MgT prompted us to investigate if
this effect of MgT is specific to the Tg mice or MgT
might also regulate BACE1 expression in WT mice. We
quantified the expression of BACE1 and NR2B (as a
positive control) in WT mice treated with MgT (sacri-
ficed at age of 18 month, MgT treatment was given for
12 months). Mice were sacrificed under basal (home-cage)
conditions or following environmental enrichment-based








































































































































































Figure 5 (See legend on next page.)
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Figure 5 Reductions by MgT treatment in amyloid plaques and BACE1 overexpression in APPswe/PS1dE9 transgenic mice (Tg mice).
(A) Upper panel left: Immunostaining of hippocampal amyloid plaque of Tg (n = 6) and Tg +MgT (n = 5). Right: Hippocampal amyloid plaque
areas were significantly lower in Tg +MgT mice. Lower panel: same as above but in the frontal cortex. Two tailed unpaired t-test, * p < 0.05.
(B) Concentrations of Aβ42 (upper panel) and Aβ40 (lower panel) monomers in CSF of Tg (n = 13) and Tg + MgT (n = 15) measured by ELISA.
(C) Left: Representative Western blots of BACE1 (β-secretase) expression in the hippocampus of mice sacrificed under home-cage conditions
(basal) or following 24 h of environmental enrichment-based stimulation (Stim). Middle: Quantitative analysis of BACE1 expression in the hippocampus
of WT, Tg and Tg +MgT mice (n = 5/group) obtained by Western blot (arbitrarily units, a.u.). Mice were sacrificed under basal conditions without
behavioral stimulation. Right: Quantitative analysis of BACE1 expression in the hippocampus of WT (n = 6), Tg (n = 6) and Tg +MgT mice (n = 5)
obtained by Western blots following behavioral stimulation. ANOVAs (Table 2) were followed by Bonferroni’s post hoc test. (D) Left: Representative
Western blots of hsAPPβ expression in the hippocampus of mice sacrificed under home-cage conditions (basal) or following 24 h of environmental
enrichment-based stimulation (Stim). Middle: Quantitative analysis of hsAPPβ expression in the hippocampus of Tg and Tg +MgT mice (n = 5/group)
obtained by Western blot (arbitrarily units, a.u.). Mice were sacrificed under basal conditions without behavioral stimulation. Right: Quantitative analysis
of hsAPPβ expression in the hippocampus of Tg (n = 6) and Tg +MgT mice (n = 5) obtained by Western blots following behavioral stimulation.
(E) Same as (D) but for β-CTF, Tg (n = 3) obtained by Western blots following behavioral stimulation. Two tailed unpaired t-tests. Data from WT mice
was displayed but not included in the analysis. Error bars show SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
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(Figure 6A). However, BACE1 expression was indiffer-
ent between WT and WT+MgT mice under basal condi-
tions and following behavioral stimulation (Figure 6B).
These results suggest that elevation of brain magnesium





















Figure 6 Effects of MgT treatment on expression of NR2B and BACE1
expression in the hippocampus of WT mice sacrificed under home-cage co
stimulation (Stim.). Middle: Quantitative analysis of NR2B expression in the
Western blot (arbitrarily units, a.u.). Mice were sacrificed under basal condit
NR2B expression in the hippocampus of WT and WT +MgT mice (n = 6/gro
(B) Left: Representative Western blots of BACE1 (β-secretase) expression in
(basal) or following 24 h of environmental enrichment-based stimulation (S
hippocampus of WT and WT +MgT mice (n = 5/group) obtained by Western
without behavioral stimulation. Right: Quantitative analysis of BACE1 expressio
by Western blots following behavioral stimulation. Two tailed unpaired t-test.Reversal of learning and memory deficits and synapse
loss in aged APPswe/PS1dE9 transgenic mice by MgT
treatment
Our previous study demonstrates that elevation of brain
magnesium can promote synaptogenesis and enhance
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hippocampus of WT and WT +MgT mice (n = 5/group) obtained by
ions without behavioral stimulation. Right: Quantitative analysis of
up) obtained by Western blots following behavioral stimulation.
the hippocampus of WT mice sacrificed under home-cage conditions
tim.). Middle: Quantitative analysis of BACE1 expression in the
blot (arbitrarily units, a.u.). Mice were sacrificed under basal conditions
n in the hippocampus of WT and WT +MgT mice (n = 6/group) obtained
Error bars show SEM. * p < 0.05.
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MgT treatment should be effective in reversing memory
deficits even when it is given at the end-stage of AD-like
pathological progression in Tg mice. To test this possibil-
ity, we prepared another group of untreated Tg, tested
their memory abilities at 23 month of age, treated them
with MgT (1 month) and reevaluated their memory abil-
ities. As expected, before treatment, Tg mice did not show
any preference toward the novel object in the STM and
LTM tests, in contrast to aged WT (Figure 7A and B).
After 1 month of MgT treatment, strikingly, the same Tg
mice exhibited significant improvement in their perform-
ance on the memory tests (Figure 7A and C). To further
prove that MgT treatment is effective in restoring cogni-
tive abilities in end-stage Tg mice, we evaluated the nest
construction abilities (a social behavior) in Tg mice before
and after MgT treatment in a separate group of mice
(23 months old). Before MgT treatment, the Tg mice ex-
hibited significant impairment in nest construction be-
havior compared with aged WT (p < 0.05, Figure 7D).
Following only 1 month of MgT treatment, nest construc-
tion behavior was restored in Tg mice (p = 0.2, Figure 7E).
These data demonstrate that learning and memory deficits
in the Tg mice might be reversible even at the end-stage of
AD-like pathological progression. However, we like to point
out a limitation of the above behavioral experiments: the
number of animals is relatively low such that the conclu-
sion drawn from these behavioral data might be subjected
to potential statistical errors. The lower number of animal
in the above experiments was due to poor survival of Tg
mice during aging (see below), although we prepared a
large number of mice at the beginning of the experiments
(see Methods). We took two measures to reduce the poten-
tial statistical errors. First, cognitive functions were
evaluated by using different behavioral tasks. Second,
the memory and nesting behaviors were evaluated in
the same groups of Tg mice before and after MgT treat-
ment. Such experimental design should give more con-
fidence in the observed effects of MgT in Tg mice.
To check whether the recovery of memory and social
behavior in Tg mice was associated with restoring the
synaptic density, we quantified synaptophysin labeled
presynaptic terminals in aged WT mice and aged Tg
mice with 1 month of MgT treatment (perfused at age
of 24 month). Strikingly, in aged Tg mice with 1 month
of MgT treatment, the presynaptic terminal density in
hippocampal DG was restored to a level comparable to
that of aged WT (p = 0.7, Figure 7F, for ANOVA analysis
see Table 2). These data suggest that elevation of brain
magnesium reversed the behavioral and structural defi-
cits even at the end-stage of the AD-like pathological
progression in Tg mice.
Besides the progressive impairment in cognitive abilities,
the lifespan of Tg mice was significantly lower than that ofWT. MgT treatment prevented the premature death of Tg
mice (Figure 7G). This longevity with more normal cogni-
tive function highlights the overall beneficial effects of
MgT treatment on body health, at least in mice.
Discussion
In our previous study, we show that elevation of brain
magnesium enhances learning and memory abilities of
young and aging rats [18]. Here, we show that elevating
brain magnesium was effective in preventing/reversing
learning and memory deterioration in APPswe/PS1dE9
transgenic mice, a model of AD-like pathologies. Com-
parison of synaptic signaling pathways among WT, Tg,
and Tg +MgT mice reveals that failure in activating
NMDAR signaling is among the major AD-like patho-
logical progression in the APPswe/PS1dE9 mice. The re-
cording studies from hippocampal slices illuminate how
elevation of brain magnesium might exert its neuroprotec-
tive effects on NMDAR signaling. Unexpectedly, we found
that elevation of brain magnesium could prevent dysfunc-
tions in APP metabolism by stabilizing the expression of
BACE1 in APPswe/PS1dE9 mice, which might also contrib-
ute to the prevention of memory deterioration by MgT
treatment. The most striking finding in the current study is
that elevation of brain magnesium was effective in restoring
synapse density at the end-stage of AD-like pathological
progression in APPswe/PS1dE9 mice, which might be re-
sponsible to the restoration of cognitive functions.
How does elevation of brain magnesium protect NMDAR
signaling in the APPswe/PS1dE9 transgenic mice?
How dysfunctions of APP metabolism lead to synaptic
dysfunctions/loss has been extensively studied [19]. The
NMDAR signaling pathway is likely to be one of the pri-
mary mechanisms underlying memory deficits in the
APPswe/PS1dE9 mice, as NMDARs play a pivotal role in
memory processes [27]. A recent study shows that pro-
tection of NMDARs is sufficient to ameliorate the mem-
ory deficits in an animal model of AD [29]. In the
current study, activation of the NMDAR signaling was
dramatically impaired in APPswe/PS1dE9 mice. This
deficit is likely to be caused by dysfunctions in Ca2+
homeostasis in these mice. Cytosolic Ca2+ level is hy-
pothesized to be elevated during AD pathologies [30].
Aβ can increase Ca2+ entry into the cell either by func-
tioning as a Ca2+ channel or by activating plasma mem-
brane Ca2+ channels [31,32], which might contribute to
elevation of cytosolic Ca2+ levels under basal conditions
in APPswe/PS1dE9 mice [33]. The increase in intracellu-
lar basal Ca2+ induces upregulation of calpain/calcine-
urin/Cdk5 neurodegenerative signaling [34]. These
signaling molecules are known as the major downregula-
tors of NMDARs for review see [35]. Hence, the down-
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Figure 7 (See legend on next page.)
Li et al. Molecular Brain 2014, 7:65 Page 12 of 20
http://www.molecularbrain.com/content/7/1/65
(See figure on previous page.)
Figure 7 Reversal by MgT treatment of behavioral and structural deficits in aged APPswe/PS1dE9 mice (Tg mice) and prevention of
their premature death. (A) Experimental design to test whether MgT treatment can reverse behavioral deficits in aged Tg mice. (B) Recognition
index of the novel object (Nov) and other familiar objects (Obj 1–3) during STM (left) and LTM (right) tests in the NORT task. WT (n = 10, ANOVA,
STM: p < 0.0001; LTM: p < 0.0001) and untreated Tg (n = 8). (C) Same as (B) and on the same mice but NORT tests were re-conducted after MgT
treatment was given to Tg mice for 1 month. ANOVA revealed significant differences in WT (n = 8, STM: p < 0.001; LTM: p < 0.05) as well as in
MgT-treated aged Tg mice (n = 7, STM: p < 0.0001; LTM: p < 0.0001). Dashed lines represent chance levels of performance (25%). ANOVA was
followed by Bonferroni’s post hoc test. (D) Nest construction social behavior in WT (n = 10) and untreated Tg mice (n = 10). (E) Same as (D) and
on the same WT (n = 7) and Tg (n = 6) mice, but after MgT treatment was given to Tg for 1 month. (F) Density of synaptophysin positive terminals
(Syn Puncta). Data from untreated aged Tg mice (from Figure 2B) were inserted (black bars) to show the effects of the 1 month treatment.
ANOVAs (Table 2) were followed by Bonferroni’s post hoc test. Error bars show SEM. * p < 0.05, ** p < 0.01, *** p < 0.001. (G) Survival curves of WT
(n = 65), Tg (n = 68) and Tg +MgT (n = 76) over 678 days of lifespan (MgT treatment started at 6 months of age). Log-rank Mantel-Cox test
revealed significant difference between Tg mice and WT (p < 0.05) as well as Tg +MgT (p < 0.01).
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or calcineurin [28].
In MgT-treated APPswe/PS1dE9 mice the NMDAR sig-
naling pathway was indifferent from WT mice. We
hypothesize that Mg2+ might inhibit and/or downregulate
calcineurin to prevent downregulation of NMDAR signal-
ing (Figure 4F). In our previous studies, we demonstrated
that elevation of [Mg2+]o reduces [Ca
2+]i, which was asso-
ciated with NMDARs activation under resting-membrane
potentials [17]. This reduction in [Ca2+]i triggers homeo-
static upregulation of NR2B-containing NMDARs in vitro
[17] and in intact animals [18]. In the current study, we
show that calcineurin is one of primary molecules mediat-
ing the effects of elevating [Mg2+]o. Since both Aβ and
[Mg2+]o regulate NMDARs by modulating the activity of
calcineurin, we propose that the protective effects of
[Mg2+]o on NMDARs in high Aβ background might be
largely mediated by preventing overactivation/overex-
pression of calcineurin. In support of the role of overacti-
vation of calcineurin in AD-like pathologies, inhibition of
calcineurin alone ameliorates the AD-like pathologies in
AD mouse model [36].How could elevation of brain magnesium lead to
downregulation of BACE1?
Intriguingly, elevation of brain magnesium not only pro-
tected NMDAR signaling, but also reduced the expression
of BACE1, a critical enzyme that cleaves APP. Recent stud-
ies suggest that dysfunctions in APP cleavage by BACE1
might be the primary factor underlying the synapse loss
and memory deficits in an AD mouse model [3] and the
degeneration of cortical neurons in vitro [4]. Inhibition [3]
or partial reduction of expression [37,38] of BACE1 rescues
synaptic/memory deficits in mouse models of AD. There-
fore, the reductions in BACE1 expression by MgT treat-
ment could contribute to the prevention of synapse loss
and improvement of cognitive function in the APPswe/
PS1dE9 mice. In the current study, the exact molecular
mechanisms underlying prevention of BACE1 overexpres-
sion by MgT treatment remain elusive.Based on the above interpretations, we attributed the
positive effects of MgT treatment on cognitive abilities
in Tg mice to its protecting actions on the NMDAR sig-
naling pathway and/or stabilizing of BACE1 expression.
However, several studies reported increased incidence of
epileptic seizures in AD patients [39] and in mouse
models of AD [40]. Recently, it was shown that low
doses of the antiepileptic drug, levetiracetam, normalize
neuronal activity and reverse cognitive deficits in a
mouse model of AD [41]. Acute infusions of high doses
of Mg2+, which elevate blood Mg2+ concentration by
~ 2.5 – 4 folds, are effective in reducing seizures acutely
in the clinical settings [42,43]. This seizure attenuation
is due to direct blockage of presynaptic calcium chan-
nels by Mg2+ [44,45]. Therefore, an alternative inter-
pretation of the positive effects of MgT treatment is that
elevation of brain magnesium increases calcium chan-
nels blockage, resulting in reductions in brain seizures.
However, for such mechanism to become effective, the
Mg2+ concentration in blood has to be elevated signifi-
cantly. In the current study oral administration of MgT
only elevates plasma magnesium by ~ 0.1 mM (Figure 1G)
and brain magnesium by 15% (Figure 1F). Since the gating
of NMDARs is very sensitive to elevations of extracellular
Mg2+ concentrations [17], the neuroprotective effects of
MgT treatment are more likely to be mediated by its ac-
tion on NMDARs.Magnesium concentration and synaptic function
Our studies demonstrate that an increase in magnesium
intake enhances memory in young rats, reverses memory
decline in aged rats [18] and prevents memory deterior-
ation a mouse model of AD (the current study). However,
it is intriguing that following long-term magnesium sup-
plementation, CSF Mg2+ concentration only increases by
15% [18] and total magnesium in brain increased by 30%
(percentage of Tg mice, Figure 1F). Can small increases in
[Mg2+]CSF have major impact on synapse density? In a
separate study, we found that increase extracellular Mg2+
by 15% leads to ~50% increase in synapse density in
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tions). These data suggest that hippocampal synapse dens-
ity might be very sensitive to small changes in extracellular
Mg2+ concentrations. Under normal physiological condi-
tions, whole body magnesium is tightly regulated by kidney
function. Daily fluctuation of plasma magnesium associ-
ated with food intake is less than 0.1 mM above a baseline
of 0.7 mM [46]. Brain magnesium is supposed to be more
stable as the blood–brain barrier isolates the brain from
daily fluctuations in blood magnesium. Therefore, despite
the high sensitivity of the synapses to Mg2+ concentration,
synapse density is likely to be stable under physiological
conditions. On the other hand, if brain magnesium is re-
duced under pathological conditions, it might have pro-
found impact on synapse density and memory function.
Interestingly, in the hippocampus of AD patients, the total
magnesium level is reduced by 18% [20]. Therefore, resto-
ration/elevation of brain magnesium in AD patients might
be beneficial for ameliorating the cognitive deficits of AD.
Methods
Experimental animals
Six hemizygous transgenic (Tg) male mice (APPswe/
PSEN1dE9)-85Dbo (referred to as ‘Tg mice’) and six non-
carrier female mice were obtained and bred in Peking
University’s laboratory animal center according to proto-
col provided by the supplier (The Jackson Laboratories).
In the breeding colony, we generated 1000 mice in total,
which were genotyped routinely to identify the Tg mice.
Overall, ~ 250 male wild type (WT) and ~ 250 male Tg
mice we prepared and majority of them were used in the
current study. Animals were housed individually in a con-
trolled environment (temperature 21 ± 1°C, humidity 50 ±
10%) under inverted light cycle (light off 9:00 AM to
9:00 PM). Behavioral experiments were performed under
red dim light. All experiments were performed on male
mice except Western blot experiments in which female
mice were used (WT: n = 48; Tg: n = 48). To conduct mo-
lecular, cellular and structural analysis, animals were sacri-
ficed at ages of 15, 18, 23 or 24 months old (for details on
each experiment see Results section). Experiments invol-
ving animals were approved by Tsinghua and Peking Uni-
versities Committees on Animal Care.
Treatment with Magnesium-L-Threonate
Magnesium-L-Threonate (MgT, Magceutics, Inc., CA,
USA) treated Tg and/or WT mice received the MgT
treatment via drinking water at a dose of ~910 mg/kg/
day (~75 mg/kg/day elemental magnesium). This dose
was determined by scaling the minimum effective dose
in rats, which we described before [18]. To monitor the
dose of MgT (mg/kg/day), water intake and body weight
were measured on daily basis (8:30 pm). The amount of
MgT necessary to reach the target dose was calculated,based on the body weight, and dissolved in the daily
drinking water (~6 ml/day/mouse) of individual animals.
The MgT treatment was started when the mice were at
the age of 6 months and lasted until animals were sacri-
ficed, excluding the end-stage treatment experiments
(Figure 7A-F) during which MgT treatment was given to
Tg mice at age of 23 months for 1 month only. Un-
treated WT and Tg mice received tap water. All mice
were maintained on standard food containing 0.15%
elemental magnesium.
Magnesium measurement in body tissues and fluids
To determine the total magnesium content (ionized and
non-ionized) in different body tissues, mice were trans-
cardially perfused and then different body tissues; such
as kidney, liver, muscles, fur, heart, and brain, were dis-
sected. Total magnesium content in different tissues was
measured using inductively coupled plasma optical emis-
sion spectroscopy (ICP-OES, Chemical Analysis Center,
Tsinghua University). To determine the free Mg2+ con-
centration in the plasma and intracellular compartment
of red blood cells, blood samples were collected from the
orbital sinus, centrifuged and plasma was collected for
measurement immediately. Mg2+ concentration in the
plasma was measured using Calmagite chromometry as we
described before [18]. The intracellular Mg2+ concentration
in red blood cell (RBC, Figure 1H) was determined by flow
cytometry (Center for Biomedical Analysis, Tsinghua Uni-
versity). The fluorescent optical density (OD) was used as
an indicator of the Mg2+ concentration in RBC. The pre-
sented data represent the average of OD of 10000 RBCs
for each mouse.
Morris water maze (MWM)
Spatial reference memory was assessed using a modified
version of the Morris water maze [47]. The pool was a cir-
cular metal tank, 100 cm in diameter, 50 cm deep, filled to
a height of 35 cm with water. Water temperature was
maintained at 21 ± 1°C degree. An acrylic platform (10 cm
in diameter) was placed inside the pool, its upper surface
1 cm below the surface of the water, so that a mouse in-
side the pool would be unable to locate it visually. The
pool was set in a moderately lit, circular enclosure made
with black curtains. Four cues with different shape and
color were placed within the maze, and other four differ-
ent cues were placed externally on the curtains. These
cues remained unchanged throughout the testing period.
The combination of proximal and distal cues was used
based on pilot experiments during which we tested the
sensitivity of WT mice to distal and proximal cues. Under
our experimental conditions the optimal learning curve
for naïve WT mice (declining from~ 60 s to ~ < 20 s over
the time course of training) was obtained upon combining
proximal and distal cues. Two protocols were used: First,
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training session for one day (day 0). This session was
followed by hidden platform training session for five days
with five trials per day (60 s per trial, 1 h inter-trial inter-
val). Each mouse was placed into the water by hand, so
that it faced the wall of the pool, at one of four starting
positions. The sequence of these positions was randomly
selected. The platform was set in the middle of one quad-
rant, equidistant from the center and the edge of the pool.
If the mouse found the platform, it was allowed to remain
there for 30 s and was then returned to its home cage. If
the mouse was unable to find the platform within 60 s, it
was guided to and placed on the platform for 30 s, the trial
was terminated, and the maximum score of 60 s was
given. In each trial, the latency to locate the hidden plat-
form was recorded using Noldus video tracking system
(Ethovision). The test trial (the memory retention test)
was carried out 24 h after the last trial of the training ses-
sion. During the test trial, the platform was removed and
each mouse was put into the pool for 60 s. The total time
spent in the target quadrant (where the platform had been
located during the training trials) was measured using the
same video system. Experiments and video analysis were
performed by experimenters who were not aware of the
genotype and the treatment of each mouse.
Second, at 15 months of age, we modified the water maze
protocol to increase the task’s difficulty. The tank-diameter
was increased to 120 cm with 12 cm diameter platform
under open-environment (curtains were removed) around
the water maze. Mice were trained for 4 days (6 trials per
day, 60 s per trial, 1 h inter-trial interval).
Novel-object recognition task
A modified version of the novel-object recognition test
[48] was used to evaluate short-/long-term recognition
memories. The apparatus consisted of a square arena
(50 × 50 × 20 cm) made of polyvinyl chloride with white
walls and floor. An overhead camera and a video re-
corder were used to monitor and record the animal’s be-
havior for subsequent analysis. Two days before the
experiment, all mice received two sessions of habituation
to the arena and test room 10 m per session/day. At day
3, each mouse was first placed in the center of the box,
and exposed to four identical objects for 5 m (sample
phase). Then the mouse was returned to its cage. For
short-term memory, a 5 m retention interval was used,
during which one of the objects was replaced by a new
novel object. The objects were placed in the same loca-
tions as the previous ones. The mice were placed back in
the box and exposed to the three familiar objects and to
the novel object for further 5 m (test phase). During this
phase, the mouse explored each of the four objects. The
exploration of an object was defined as directing the nose
to the object at a distance of 2 cm and/or touching it withthe nose and forepaws. Turning around the object without
direct exploration was not considered. The session was re-
corded on video, and the frequency of object exploration
was subsequently measured by the experimenters who
were blind to the treatment and genotype of each group.
Recognition index was calculated as percentage ratio of
time of each object over total exploration time. The box
and objects were cleaned with 20% ethanol between trials
to prevent the build-up of olfactory cues. For long-term
memory same procedure was used but the retention inter-
val was 24 h and completely different objects were used.
Nest construction test
Mice were individually housed in plastic cages with ap-
proximately 1 cm of woodchip bedding lining the floor.
Two hours after the onset of the dark phase, individual
cages were supplied with a 20 cm× 20 cm piece of paper
towel torn into approximately 5 cm × 5 cm squared pieces.
Cages were observed for the next 12 h. Pictures were
taken for documentation before the evaluation. Nest con-
struction was scored along a system as followed: 1 = no
biting or tears on the paper, 2 =mild biting and/or tears
without gathering, 3 =moderate biting and/or tears on the
paper with moderate gathering of pieces, 4 = the majority
of papers torn and gathered in a good manner, and 5 = the
vast majority of paper torn into approximately 1 cm pieces
and grouped into a corner of the cage. Twenty-four hours
after the first nest construction test, MgT treatment of the
Tg mice started and lasted for 1 month, whereupon the
second test was conducted. Mice were tested in counter-
balanced groups of mixed genotypes. Nest construction
was scored by experimenters who were unaware of the
treatment and genotype of each group.
Brains preparation for electron microscopy and staining
of presynaptic puncta and amyloid plaques
Mice (under home cage conditions) were anesthetized
with chloral hydrate and perfused transcardially with
physiological saline followed by 4% paraformaldehyde in
0.1 M phosphate buffer (pH 7.4). The left hemispheres
were immersed in the same fixative overnight, embedded
in paraffin, and were prepared for presynaptic puncta and
amyloid plaques immunostaining. The right hemispheres
were prepared for transmission electron microscopy.
Transmission electron microscopic analysis
The right hemisphere was sectioned (500 μm thick cor-
onal) to expose hippocampus. After brief rinse in 0.1 M
sodium cacodylate buffer (SCB, pH 7.4), samples were
immersion-fixed overnight in 2.5% glutaraldehyde and
2% paraformaldehyde in 0.1 M SCB containing 1% tan-
nic acid. After rinsing in SCB and postfixation for 1 h in
1% osmium tetroxide, 0.1 M SCB, the hippocampal sec-
tions were dehydrated using a series of acetone dilutions
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tions (500 nm) stained with toluidine blue were used to
locate and trim granule cell layer and molecular layer of
dentate gyrus in the hippocampus. Ultrathin sections
(60 nm) stained with uranyl acetate and lead citrate,
were examined with a JEOL-1200EX transmission elec-
tron microscope (Japan Electric Optical Laboratory) oper-
ated at 80 kV. Two sets of images were randomly captured
at magnifications of 12,000 and 30,000, respectively. Scale
bars were taken from scans of original electron micrograph
negatives. Quantitative analysis was conducted on the
digital EM micrographs of the same magnification from
the outer molecular layer of the hippocampus dentate
gyrus from all mice. The measurement was performed by
experimenters who were not aware of the genotyping/
treatment and was assisted by MetaMorph software (Mo-
lecular Devices). Synapses were identified on the micro-
graphs by the presence of postsynaptic density (PSD) and
at least two synaptic vesicles in the axon terminal in close
proximity. For the analysis of the synaptic density, the sets
of lower magnification micrographs were used (24–26 mi-
crographs for each mouse).
Estimation of density of presynaptic puncta
Density of synaptophysin- /glutamic acid decarboxylase
65kD (GAD65)-immunoreactive presynaptic terminals
were quantified as we previously described for synapto-
physin positive puncta [18]. Coronal sections (6 μm
thick) from the left hemisphere were deparaffinized in
xylene and rehydrated using a descending ethanol series
followed by epitope retrieval with citrate buffer. After
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Western blot HRP-conjugated Goat anti-
HRP-conjugated Goat anti-secondary antibody) in PBS with 0.1% Triton X-100, tis-
sue sections were incubated overnight with the primary
antibody (see Table 3 for detailed information on each
antibody) in PBS with 3% serum at 4°C. After washing in
PBS, sections were incubated with CF488-conjugated
(Biotium Inc., CA, USA) secondary antibody (Table 3).
After washing with PBS, sections were coverslipped with
anti-fade mounting medium (Vectashield). Slides were
coded until the completion of data analysis. Stained
brain sections were imaged with Olympus IX-70 con-
focal microscope with the 60 ×; water lens (N/A = 1.2) at
zoom × 3, generating an image with 78.6 × 78.6 μm di-
mension. Serial z-sectioning was performed (thickness of
0.6 μm) and the best three z-sections (with highest number
of puncta) were collected and merged into a single image.
Therefore, volume of brain tissue per image is ~78.6 ×
78.6 × 1.8 μm3. The number of synapses in the DG and
CA1 subregions was estimated from the obtained images
using Image-Pro-Plus software (Media Cybernetics). Back-
ground levels were equalized and special filters to separate
fluorescent puncta were applied. Settings, for each image,
were adjusted to maximize the number of detected fluores-
cent puncta. Mean puncta number per 1000 μm2 was used
as an estimate of the presynaptic puncta density.
Amyloid plaque immunostaining
Plaque burden was assessed by immunohistochemistry on
paraffin-embedded sections using monoclonal anti-Aβ
antibodies 4G8 and/or 6E10 (Signet), as described previ-
ously [22]. Prior to immunostaining, sections were depar-
affinized in xylene and washed in 100% ethanol, 95%
ethanol, 70% ethanol, and water. Endogenous peroxidaseHost Dilution Source
Mouse 1:500 Millipore
Rabbit 1:500 Millipore
Rabbit 1:6000 Santa Cruz
Rabbit 1:1000 Cell Signaling
Rabbit 1:1000 Cell Signaling
Rabbit 1:50 Cell Signaling
Rabbit 1:1000 Cell Signaling
Rabbit 1:6000 Cell Signaling




ti-Mouse IgG(H + L) 1:200 Biotium
ti-Rabbit IgG(H + L) 1:200 Biotium
Rabbit IgG(H + L) 1:20000 ZSGB-BIO
Mouse IgG(H + L) 1:25000 CST
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in 3% H2O2 in methanol followed by epitope retrieval with
citrate buffer and 5 m incubation in 85% formic acid.
After rinse in PBS, nonspecific epitopes were blocked with
normal horse serum. Then sections were incubated with
primary antibody 4G8 and/or 6E10 (1:500 dilution) in PBS
with 3% BSA and incubated over night at 4°C in a humid
chamber. Sections were then washed in PBS and incubated
with biotinylated secondary antibodies and avidin-biotin-
peroxidase as described by the manufacturer (Vectastain
Elite ABC Kit) and visualized with diaminobenzidine tetra-
chloride (DAB). Stained sections containing hippocampus
were examined with a Leica DM IRB inverted research
microscope, using 5 × objective, and digital images were
captured with a Retiga 2000R digital camera (Qcaputure).
The areas covered by amyloid plaque in the hippocampal
formation and frontal cortex were calculated using Image-
Pro Plus. The area of interest was manually outlined, and
the percentage of area occupied by Aβ plaque, in the
hippocampus and frontal cortex, was calculated.
Aβ42 and Aβ40 concentrations in the cerebrospinal fluid
To determine the concentration of Aβ42 and 40 mono-
mers in the cerebrospinal fluid, mice were anesthetized
with chloral hydrate (400 mg/kg, i.p.) and then the CSF
was manually obtained from the cisterna magna by the
interruption of the atlanto-occipital membrane using a
recording pipettes (diameter 0.5 μm). CSF samples (8 μl/
mouse) were collected and stored at −20°C until measure-
ment was performed. The Aβ42 and Aβ40 monomers
concentrations were determined using ELISA kit (human
β amyloid [1-40] and [1-42] kits, Wako, Osaka, Japan).
The procedure was performed with complete adherence
to the manufacturer’s instructions.
Environmental enrichment-based stimulation for Western
blot analyses
For quantitative Western blot experiments (Figures 3,
5C-E and 6), mice were exposed to environmental
enrichment-based behavioral stimulation for 24 h before
being sacrificed. Mice were housed individually in stand-
ard cages (300 cm2 floor space), the stimulus of enrich-
ment was divided into two phases: grouping (for 21 h)
and physical-training (for 3 h). During the grouping
phase, mice were group-housed in a large cage (5–6
mice/cage, 70 cm*60 cm*30 cm) without any running
wheels or toys. During the physical-training phase the
mice in the large cage were given running wheels, play
tubes, and wood boxes.
Western blot
Frozen (−80°C) hippocampal tissues were homogenized
and equal amounts of proteins were resolved on poly-
acrylamide gel, then transferred to PVDF membranes(Millipore). Membranes were blocked and then probed
with primary antibodies against NR2B (H-50, sc-9057,
from Santa Cruz Biotechnology), BACE1 (D10E5),
CREB, pCREB, CaMKII, pCaMKII, GAPDH (all from
Cell Signaling Technology), sAPPβ (IBL) or β-CTF
(6E10, Signet, see Table 3) overnight at 4°C. Membranes
were then incubated with an HRP-conjugated secondary
antibody (ZSGB-BIO or CST, see Table 3) at room
temperature. Protein bands were detected by ECL detec-
tion reagent (RPN2232; GE Healthcare) and captured on
an autoradiography film (Kodak). Integrated optical
density was determined using Image-Pro Plus software
6.0 (Media Cybernetics). Standard curves were con-
structed to establish that we operated within the linear
range of the detection method. Co-detection of GAPDH
on the same membrane served as a loading control.
Quantitative analysis was performed by experimenters
blind to the treated and/or genotype group.
In vivo and in vitro recording
Input–output relationship in CA1 synapses in vivo
Mice were anesthetized with urethane (2 g/kg, i.p.). The
animals were fixed in a stereotaxic apparatus (Narishige
SN-2, Japan). Field postsynaptic potentials (fPSPs) were
recorded from the stratum radiatum in CA1 following
electrical stimulation of Schaffer collateral–commissural
pathway. The optimal electrode placement was deter-
mined using electrophysiological criteria as described
before [49]. The recording electrode was positioned at
2.3 mm posterior to bregma, 1.75 mm lateral to midline
and the depth of recording electrode was about 1.6 mm
from dura. The stimulating electrode was positioned
1.7 mm posterior to bregma and 1.6 mm lateral to mid-
line and about 1.8 mm from dura. The positions of the
recoding and stimulation electrodes were confirmed by
trailing the electrodes in brain sections from representa-
tive animals. A single square pulse of voltage at low fre-
quency (0.066 Hz, 0.2 ms duration) was used to evoke
fPSPs and the intensity of the test stimulus was adjusted
to produce ~50-55% of maximum response.
Slice preparation for in vitro recordings
Acute coronal slices of hippocampus (400 μm thick)
were prepared from 4 weeks old male C57BL/6 mice as
described before [50]. Briefly, slices were transferred and
submerged in a recovery chamber containing oxygenated
(95% O2 and 5% CO2) artificial cerebrospinal fluid
(ACSF, mM): 125 NaCl, 2.5 KCl, 2 CaCl2, 1.2 or 0.8
MgCl2, 26 NaHCO3, 1.25 NaH2PO4, 25 glucose. The
extracellular magnesium concentration ([Mg2+]o) varied
according to the experimental conditions. Slices were in-
cubated in ACSF containing either physiological extra-
cellular magnesium concentration ([Mg2+]o = 0.8 mM)
or high [Mg2+]o (1.2 mM), at 32°C for 1 h and then at
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of the pre-incubation conditions, the recording was per-
formed under 1.2 mM [Mg2+]o to avoid any potential
acute effect of elevating [Mg2+]o.
Amyloid-β and FK506
Application of Amyloid-β and FK506 was done as de-
scribed before [28]. Briefly, Amyloid-β42 monomer
(1 μM, Amyloid β-Protein Fragment 1–42, sigma) and/
or FK506 (10 μM, Sigma) were applied into the ACSF
after the 3 h recovery period and for 1 h before record-
ing started.
Whole-cell recordings in vitro
Experiments were performed in a recording chamber on
the stage of a microscope (Eclipse FN1, Nikon) with infra-
red DIC optics (IR1000, DAGE-MTI) for visualizing whole-
cell patch-clamp recordings. EPSCs were recorded from
CA1 pyramidal neurons, using an EPC-9 amplifier with
Pulse v8.65 software (HEKA Elek., Lambrecht, Germany),
while stimulating the Schaffer collateral-commissural path-
way. A moderate constant amplitude stimulus, by Stimulus
Isolator A365 (World Precision Instruments, Sarasota, FL
USA) with bipolar tungsten stimulating electrode, was used
to stimulate axonal fibers and a population of synapses.
The extracellular solution also contained picrotoxin
(100 μM, Sigma) to block fast GABAergic inhibition. The
recording pipettes (3–5 MΩ) were filled with solution con-
taining (mM): 130 Cs-gluconate, 4 NaCl, 0.5 MgCl2, 5
EGTA, 10 HEPES, 5 MgATP, 0.5 Na3GTP and 5 QX-314
(adjusted to pH 7.3 with CsOH and osm. 290–295 with
double distilled water).
For EPSCNMDA/EPSCAMPA experiments, after whole-cell
patch-clamp, neurons were voltage clamped at −70 mV to
record the EPSCAMPA, and then were clamped at +50 mV
to record the EPSCNMDA (with liquid junction potential
correction). EPSCs were induced by repetitive stimulations
at 0.1 Hz. The peak amplitude of EPSCAMPA was deter-
mined at the peak of the EPSCs recorded at −70 mV,
and the peak amplitude of EPSCNMDA was determined
at +50 mV and 200 ms after stimulation. The INMDA/AMPA
ratio was calculated from the recorded data of individual
neurons.
Statistics
Learning curves in the water maze task were analyzed
using Two-way ANOVA (treatment x trials) repeated
measure. The water maze memory tests, NORT, magne-
sium contents in brain tissue, electron microscopy,
fluorescent immunostaining and Western blot data were
analyzed using One-way ANOVA. ANOVAs were
followed by Bonferroni’s post hoc test. All data involved
comparing two groups were analyzed using two-tailedunpaired t-test. P value less than 0.05 was considered
statistically significant.
Additional files
Additional file 1: Figure S1. The raw data for Western Blot in
Figure 5C-E.
Additional file 2: Figure S2. The raw data for Western Blot in Figure 6.
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